Home>>Lipids>> Hydroxy/Hydroperoxy/Epoxy/Oxo Eicosanoids>>11(S)-HETE

11(S)-HETE (Synonyms: 11(S)-Hydroxyeicosatetraenoic Acid)

Catalog No.GC40446

11(S)-HETE is an oxylipin and the (S) enantiomer of 11(R)-HETE. It is formed non-enzymatically from arachidonic acid.

Products are for research use only. Not for human use. We do not sell to patients.

11(S)-HETE Chemical Structure

Cas No.: 54886-50-9

Size Price Stock Qty
25μg
$197.00
In stock
50μg
$375.00
In stock
100μg
$552.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

11(S)-HETE is an oxylipin and the (S) enantiomer of 11(R)-HETE. It is formed non-enzymatically from arachidonic acid.[1] Levels of 11(S)-HETE are higher than those of 11(R)-HETE in isolated human plasma and serum and in LPS-stimulated isolated human plasma. Serum labels of 11(S)-HETE decrease in patients with allergic rhinitis after one year of double-mite subcutaneous immunotherapy (DM-SCIT) and are associated with an improved quality of life in regards to rhinoconjunctivitis.[2]

References:
1. Mazaleuskaya, L.L., Salamatipour, A., Saratopoulou, D., et al. Analysis of HETEs in human whole blood by chiral UHPLC-ECAPCI/HRMS. J. Lipid Res. 59(3), 564-575 (2018).
2. Zheng, P., Yan, G., Zhang, Y., et al. Metabolomics reveals process of allergic rhinitis patients with single- and double-species mite subcutaneous immunotherapy. Metabolites 11(9), 613 (2021).

Reviews

Review for 11(S)-HETE

Average Rating: 5 ★★★★★ (Based on Reviews and 23 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 11(S)-HETE

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.